NR3C2 and hydrops fetalis: Large clinical studies like RALES, EPHESUS and EMPHASIS-HF demonstrate a reduction in mortality and hospitalization rate of cardiovascular patients after treatment with MR antagonists independently of blood pressure or electrolyte homeostasis1,2,29–31.